Brief: Cyxone: Top-Line Results From Phase 2 Study Of Rabeximod In Covid-19 Patients

Cyxone AB

06/12/2021 07:53

Dec 6 (Reuters) - Cyxone AB  CYXO.ST :
    * CYXONE PRESENTS TOP-LINE RESULTS FROM A PHASE 2 STUDY OF
RABEXIMOD IN COVID-19 PATIENTS
    * SECONDARY AND EXPLORATORY ENDPOINTS WILL BE ANALYZED TO
ASSESS
BENEFIT OF RABEXIMOD IN COVID-19
    * PRIMARY ENDPOINT WAS TO DOCUMENT DIFFERENCE OF PROPORTION
OF
SUBJECTS ALIVE AND FREE OF RESPIRATORY FAILURE AT DAY 28 BETWEEN
PLACEBO (STANDARD OF CARE TREATMENT) AND RABEXIMOD PLUS STANDARD
OF CARE
    * NO SERIOUS ADVERSE EVENTS CONNECTED TO RABEXIMOD TREATMENT
WERE
OBSERVED AND DRUG CANDIDATE WAS WELL-TOLERATED IN INFECTED
PATIENTS
    * TOPLINE DATA ANALYSIS SHOWED THAT ALMOST ALL PATIENTS WERE
ALIVE
AND FREE OF RESPIRATORY FAILURE AT DAY 28 IN DIFFERENT TREATMENT
ARMS
    * ENDPOINT ASSESSMENT DID NOT REVEAL IF RABEXIMOD HAS
ADDITIONAL
BENEFITS OVER STANDARD OF CARE AT DAY 28

Source text for Eikon:  ID:nWkr3brbgq 
Further company coverage:  CYXO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))